Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

New England Journal of Medicine

Volumn 361, Issue 2, 2009, Pages 123-134

  Fong, Peter C ^a   Boss, David S ^f   Yap, Timothy A ^a   Tutt, Andrew ^b,c   Wu, Peijun ^b,c   Mergui Roelvink, Marja ^f   Mortimer, Peter ^d   Swaisland, Helen ^e   Lau, Alan ^d   O'Connor, Mark J ^d   Ashworth, Alan ^b   Carmichael, James ^d   Kaye, Stan B ^a   Schellens, Jan H M ^f,g   De Bono, Johann S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d KuDOS Pharmaceuticals   (United Kingdom)

^e ASTRAZENECA   (United Kingdom)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

^g UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 2281; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; KU 0059436; MITOMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; UNCLASSIFIED DRUG; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISTRIBUTION VOLUME; DIZZINESS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; ENZYME INHIBITION; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MESOTHELIOMA; METASTASIS; MOOD CHANGE; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NAUSEA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; SOMNOLENCE; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; VOMITING;

EID: 67650471685     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0900212     Document Type: Article

References (31)

1. Lindahl T. Instability and decay of the primary structure of DNA. Nature 1993;362:709-15.
2. Jackson SP. Detecting, signalling and repairing DNA double-strand breaks. Biochem Soc Trans 2001;29:655-61.
3. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001;411:366-74.
4. Amé JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004;26:882-93.
5. Dantzer F, de La Rubia G, Ménissier-De Murcia J, Hostomsky Z, de Murcia G, Schreiber V. Base excision repair is impaired in mammalian cells lacking poly(ADP-ribose) polymerase-1. Biochemistry 2000;39:7559-69.
6. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66:8109-15.
7. Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006;25:5864-74.
8. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003;348:2339-47.
9. Stratton JF, Gayther SA, Russell P, et al. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 1997;336:1125-30.
10. Edwards SM, Kote-Jarai Z, Meitz J, et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 2003;72:1-12.
11. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
12. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7. [Erratum, Nature 2007;447:346.]
13. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008;26:3785-90.
14. Tutt AN, Lord CJ, McCabe N, et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 2005;70:139-48.
15. Brody LC. Treating cancer by targeting a weakness. N Engl J Med 2005;353:949-50.
16. Evers B, Drost R, Schut E, et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008;14:3916-25.
17. Menear KA, Adcock C, Barlter R, et al. 4-[3-(4- Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 2008;51:6581-91.
18. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997;89:1138-47.
19. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda, MD: Cancer Therapy Evaluation Program, 2006. (Accessed June 5, 2009, at http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3. pdf.)
20. Camidge DR, Randall KR, Foster JR, et al. Plucked human hair as a tissue in which to assess pharmacodynamic end points during drug development studies. Br J Cancer 2005;92:1837-41.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
22. Rustin GJ, Quinn M, Thigpen T, et al. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2004;96:487-8.
23. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-7. [Errata, J Clin Oncol 2000;18:2644,2007;25:1154.]
24. Fernandez-Capetillo O, Celeste A, Nussenzweig A. Focusing on foci: H2AX and the recruitment of DNA-damage response factors. Cell Cycle 2003;2:426-7.
25. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005;5:689-98.
26. Venkitaraman AR. A growing network of cancer-susceptibility genes. N Engl J Med 2003;348:1917-9.
27. Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007;26:2126-32.
28. Press JZ, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008;8:17.
29. Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008;451:1111-5.
30. Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008;451:1116-20.
31. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004;4:814-9.